



# Praluent in India

*The CDSCO named-patient coordination pathway — indicative 2026*

CARDIOLOGY · HYPERCHOLESTEROLAEMIA

## The clinical situation

Praluent (alirocumab) is an FDA-approved fully human monoclonal antibody to PCSK9 that increases hepatic LDL-receptor availability, indicated for primary hypercholesterolaemia (including heterozygous familial hypercholesterolaemia) and to reduce MI, stroke, and unstable-angina hospitalisation in adults with established cardiovascular disease. Manufactured by Regeneron/Sanofi. Standard dosing is 75 mg SC every two weeks, titratable to 150 mg every two weeks or 300 mg every four weeks; refrigerated storage, patient-administered auto-injector.

## The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating cardiologist or lipidologist documents LDL-C trajectory on maximally-tolerated statin ± ezetimibe and confirms PCSK9-inhibitor eligibility.
- 2 Treating centre confirmed.** An Indian tertiary cardiology centre or lipid clinic in Mumbai, Delhi, Bengaluru, or Chennai accepts the case and writes the prescription.
- 3 CDSCO named-patient application.** Clinical rationale, patient reference, product details, and cold-chain plan are filed under CDSCO's personal-import pathway; Form-10/Form-12 as applicable.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; temperature-monitored 2-8°C shipment.
- 5 Arrival & administration.** Patient self-administers SC at home after nurse training; LDL-C recheck at 4-8 weeks, then quarterly.

## Indicative economics

**Reference US cash-pay range:** USD 500–600 per 2-week supply (one auto-injector). CDSCO documentation, cold-chain logistics, and concierge coordination are incremental. Full transparent quote at intake.

## Indicative first-dose timing

**7–14 days** from a complete CDSCO application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and CDSCO review. **Logistics.** Temperature-monitored cold-chain shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating cardiologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Praluent × India first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/praluent-india.html](https://reservemed.com/access-guides/praluent-india.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team